| 1 |
Kwak JH, Lee SY, Choi JW; Korean Society of Kawasaki Disease. Clinical features, diagnosis, and outcomes of multisystem inflammatory syndrome in children associated with coronavirus disease 2019. Clin Exp Pediatr 2021;64:68-75.
DOI
|
| 2 |
Bunyavanich S, Do A, Vicencio A. Nasal gene expression of angiotensin-converting enzyme 2 in children and adults. JAMA 2020;323:2427-9.
DOI
|
| 3 |
Zimmermann P, Curtis N. Coronavirus infections in children including COVID-19. Ped Infec Dis J 2020;39:355-68.
DOI
|
| 4 |
Verdoni L, Mazza A, Gervasoni A, Martelli L, Ruggeri M, Ciuffreda M, et al. An outbreak of severe Kawasaki-like disease at the Italian epicenter of the SARS-CoV-2 epidemic: an observational cohort study. Lancet 2020;395:1771-8.
DOI
|
| 5 |
South AM, Diz DI, Chappell MC. COVID-19, ACE2, and the cardiovascular consequences. Am J Physiol Heart Circ Physiol 2020;318:H1084-H1090.
DOI
|
| 6 |
Yan R, Zhang Y, Li Y, Xia L, Guo Y, Zhou Q. Structural basis for the recognition of the SARS-CoV-2 by full length human ACE-2. Science 2020;367:1444-8.
DOI
|
| 7 |
World Health Organization (WHO). Multisystem inflammatory syndrome in children and adolescents with COVID-19. Scientific brief [Internet]. Geneva (Switzerland): WHO; 2020 May [cited 2020 May 31]. Available from: https://www.who.int/publications-detail/multisysteminflammatory-syndrome-in-children-and-adolescents-with-covid-19.
|
| 8 |
Riphagen S, Gomez X, Gonzalez-Martinez C, Wilkinson N, Theocharis P. Hyperinflammatory shock in children during COVID-19 pandemic. Lancet 2020;395:1607-8.
DOI
|
| 9 |
European Centre for Disease Prevention and Control (ECDC). Paediatric inflammatory multisystem syndrome and SARS-CoV-2 infection in children - 15 May 2020 [Internet]. Solna (Sweden): ECDC; 2020 [cited 2020 May 31]. Available from: https://www.ecdc.europa.eu/en/publications-data/paediatric-inflammatory-multisystem-syndrome-andsars-cov-2-rapid-risk-assessment.
|
| 10 |
U.S. Centers for Disease Control and Prevention (CDC). Multisystem inflammatory syndrome in children (MIS-C) associated with coronavirus disease 2019 (COVID-19) [Internet]. Bethesda (MD): CDC; 2020 May [cited 2020 May 31]. Available from: https://emergency.cdc.gov/han/2020/han00432.asp.
|
| 11 |
Guo J, Huang Z, Lin L, Lv J. Coronavirus Disease 2019 (COVID-19) and cardiovascular disease: a viewpoint on the potential influence of angiotensin-converting enzyme inhibitors/angiotensin receptor blockers on onset and severity of severe acute respiratory syndrome coronavirus 2 infection. J Am Heart Assoc 2020;9:e016219.
DOI
|
| 12 |
Dalan R, Bornstein SR, El-Armouche A, Rodionov RN, Markov A, Wielockx B, et al. The ACE-2 in COVID-19: foe or friend? Horm Metab Res 2020;52:257-63.
DOI
|
| 13 |
Garg M, Royce SG, Lubel JS. Letter: intestinal inflammation, COVID-19 and gastrointestinal ACE2-exploring RAS inhibitors. Aliment Pharmacol Ther 2020;52:569-70.
DOI
|
webmaster
